Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 258-753-8 | CAS number: 53770-52-8
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
As a worst case, absorption of zinc 3,5-bis(α-methylbenzyl)salicylate in humans via the oral and inhalation routes is assumed to be 100%. Absorption by the dermal route is assumed to be 10% based on the substance having a molecular weight > 500.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 10
- Absorption rate - inhalation (%):
- 100
Additional information
Toxicokinetic parameters such as uptake, distribution, metabolism and excretion form the essential toxicological profile of a substance. An approximate indication of the toxicokinetic pattern can be gained from the results of basic toxicity testing. The assessment of the toxicokinetic properties of zinc 3,5-bis(α-methylbenzyl)salicylate detailed below is based on the results obtained for the physical/chemistry and toxicological endpoints.
In the acute oral toxicity study and the repeated dose toxicity studies with the test substance, signs of toxicity were observed indicating that the substance is absorbed by this route. As a worst case, absorption via the oral route is assumed to be 100%. The molecular weight (754 to 757) of the test substance is > 500. Consequently, absorption via the dermal route is assumed to be 10%. Signs of systemic toxicity were observed in the oral toxicity studies with the substance therefore it is likely that the substance will also be absorbed if it is inhaled, however, the likelihood that inhalable atmospheres may be generated is low. As a worst case, absorption via the inhalation route is assumed to be 100%.
The substance is considered to be lipophilic (based on log Kow >0) therefore it is likely to distribute into cells and the intracellular concentration may be higher than extracellular concentration particularly in fatty tissues. Zinc 3,5-bis(α-methylbenzyl)salicylate contains zinc and zinc is distributed to all tissues and tissue fluids in humans.
The organic component of the test substance is likely to undergo metabolism in the liver and other organs with the resultant metabolites eliminated by the kidneys in the urine. Bioaccumulation of the test substance is not expected based on its low log Kow value, water solubility and predicted metabolism.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
